TY - JOUR
T1 - Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy
T2 - Arrhythmia-free survival after endo-epicardial substrate based mapping and ablationablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy arrhythmia-free survival after endo-epicardial substrate based mapping and ablation
AU - Bai, Rong
AU - Biase, Luigi Di
AU - Shivkumar, Kalyanam
AU - Mohanty, Prasant
AU - Tung, Roderick
AU - Santangeli, Pasquale
AU - Carlos, Luis Saenz
AU - Vacca, Miguel
AU - Verma, Atul
AU - Khaykin, Yariv
AU - Mohanty, Sanghamitra
AU - Burkhardt, J. David
AU - Hongo, Richard
AU - Beheiry, Salwa
AU - Russo, Antonio Dello
AU - Casella, Michela
AU - Pelargonio, Gemma
AU - Santarelli, Pietro
AU - Sanchez, Javier
AU - Tondo, Claudio
AU - Natale, Andrea
PY - 2011/8
Y1 - 2011/8
N2 - Background-In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, freedom from ventricular arrhythmias (VAs) after endocardial ablation is limited. We compared the long-term freedom from recurrent VAs by using endocardial-alone ablation versus endo-epicardial substrate-based ablation. Methods and Results-Forty-nine patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing ablation of ventricular tachycardia (VT) were divided into 2 groups: endocardial-alone ablation (group 1, n=23) and endo-epicardial ablation (group 2, n=26). All patients had an implantable cardioverter-defibrillator (ICD). Conventional and 3D mappings were used to determine the mechanism of induced VTs and to identify area of "scar" or "abnormal" myocardium. All critical sites responsible for VTs and points with "abnormal" potential were targeted for ablation from endocardium (group 1) or from both endocardium and epicardium (group 2). The procedural end point was noninducibility of sustained, monomorphic VT with isoproterenol. The presence of frequent premature ventricular contractions at the end of ablation was recorded. Patients were followed up by ECG, Holter, and ICD interrogation. After a follow-up of at least 3 years, freedom from VAs or ICD therapy was 52.2% (12/23) in group 1 and 84.6% (22/26) in group 2 (P=0.029), with 21.7% (5/23) and 69.2% (18/26) patients off antiarrhythmic drugs (P<0.001), respectively. Compared with patients with no premature ventricular contractions after ablation, patients with frequent premature ventricular contractions after ablation were more likely to have VA recurrence/ICD therapy [3/33 (9%) versus 12/16 (75%); log-rank P<0.001]. Conclusions-An endo-epicardial- based ablation strategy achieves higher long-term freedom from recurrent VAs off antiarrhythmic therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy when compared with endocardial-alone ablation. The presence of ≥10 premature ventricular contractions per minute after ablation is associated with more VA recurrence.
AB - Background-In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, freedom from ventricular arrhythmias (VAs) after endocardial ablation is limited. We compared the long-term freedom from recurrent VAs by using endocardial-alone ablation versus endo-epicardial substrate-based ablation. Methods and Results-Forty-nine patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing ablation of ventricular tachycardia (VT) were divided into 2 groups: endocardial-alone ablation (group 1, n=23) and endo-epicardial ablation (group 2, n=26). All patients had an implantable cardioverter-defibrillator (ICD). Conventional and 3D mappings were used to determine the mechanism of induced VTs and to identify area of "scar" or "abnormal" myocardium. All critical sites responsible for VTs and points with "abnormal" potential were targeted for ablation from endocardium (group 1) or from both endocardium and epicardium (group 2). The procedural end point was noninducibility of sustained, monomorphic VT with isoproterenol. The presence of frequent premature ventricular contractions at the end of ablation was recorded. Patients were followed up by ECG, Holter, and ICD interrogation. After a follow-up of at least 3 years, freedom from VAs or ICD therapy was 52.2% (12/23) in group 1 and 84.6% (22/26) in group 2 (P=0.029), with 21.7% (5/23) and 69.2% (18/26) patients off antiarrhythmic drugs (P<0.001), respectively. Compared with patients with no premature ventricular contractions after ablation, patients with frequent premature ventricular contractions after ablation were more likely to have VA recurrence/ICD therapy [3/33 (9%) versus 12/16 (75%); log-rank P<0.001]. Conclusions-An endo-epicardial- based ablation strategy achieves higher long-term freedom from recurrent VAs off antiarrhythmic therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy when compared with endocardial-alone ablation. The presence of ≥10 premature ventricular contractions per minute after ablation is associated with more VA recurrence.
KW - Ablation
KW - Arrhythmogenic right ventricular dysplasia
KW - Cardiomyopathy
KW - Epicardial
KW - Premature ventricular contraction
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=80054043363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054043363&partnerID=8YFLogxK
U2 - 10.1161/CIRCEP.111.963066
DO - 10.1161/CIRCEP.111.963066
M3 - Article
C2 - 21665983
AN - SCOPUS:80054043363
SN - 1941-3149
VL - 4
SP - 478
EP - 485
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
IS - 4
ER -